Pfizer’s monthly obesity drug berobenatide shows up to 12% weight loss in mid-stage VESPER-3 study

Detailed data from Pfizer's mid‑stage VESPER-3 trial indicate that the company’s monthly‑dosed obesity candidate, berobenatide, continues to demonstrate weight‑loss potential. The drug, originally acquired from biotech Metsera, was given to patients with obesity in a weekly regimen for the first 12 weeks before switching to higher monthly doses through week 28.

Among participants who remained on therapy, average weight loss reached up to 12.1% of body weight. The study design allowed investigators to assess both the safety of the dosing switch and the efficacy of the monthly schedule compared with the earlier weekly dosing.

While the results are encouraging, analysts note that the drug’s competitive position remains uncertain. Weekly injectable obesity treatments already on the market and other candidates in development may achieve greater weight loss, leaving questions about how berobenatide will be positioned in the crowded field.